STOCK TITAN

Puma Biotechnology, Inc. - $PBYI STOCK NEWS

Welcome to our dedicated page for Puma Biotechnology news (Ticker: $PBYI), a resource for investors and traders seeking the latest updates and insights on Puma Biotechnology stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Puma Biotechnology's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Puma Biotechnology's position in the market.

Rhea-AI Summary
Puma Biotechnology, Inc. (PBYI) commences ALISertib in CAncer Phase II trial for small cell lung cancer patients who have progressed on previous treatments. The trial aims to evaluate alisertib monotherapy's efficacy with primary and secondary endpoints focusing on response rates, survival, and biomarker analysis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.36%
Tags
-
Rhea-AI Summary
Puma Biotechnology, Inc. (PBYI) CEO Alan H. Auerbach to present at B. Riley Securities 4th Annual Oncology Conference on January 18, 2024. Replay available on company website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.55%
Tags
conferences
-
Rhea-AI Summary
Puma Biotechnology, Inc. (PBYI) announced the design of the Phase II trial of alisertib for the treatment of patients with HER2-negative, hormone receptor-positive metastatic breast cancer. The trial will evaluate alisertib in combination with endocrine treatment and is expected to initiate in the second half of 2024. The primary efficacy endpoints will include objective response rate, duration of response, disease control rate, and progression-free survival. The Company plans to engage with global regulatory agencies for the design of a pivotal Phase III trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.99%
Tags
Rhea-AI Summary
Puma Biotechnology announced the grant of an inducement restricted stock unit award to a new non-executive employee. The award covers 15,000 shares of Puma common stock and vests over a three-year period. It was granted under Puma's 2017 Employment Inducement Incentive Award Plan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.2%
Tags
none
-
Rhea-AI Summary
Puma Biotechnology, Inc. (NASDAQ: PBYI) reported financial results for Q3 2023, with product revenue of $51.6 million, a decrease from $54.3 million in Q3 2022. Net income for Q3 2023 was $5.8 million, compared to a net loss of $0.4 million in Q3 2022. The company had cash, cash equivalents, and marketable securities of $85.0 million as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.65%
Tags
-
Rhea-AI Summary
Puma Biotechnology to host conference call following release of Q3 2023 financial results
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.28%
Tags
conferences earnings
Rhea-AI Summary
Puma Biotechnology presents Phase I/II trial results of alisertib plus pembrolizumab for treatment of Rb-deficient head and neck squamous cell carcinoma at AACR-NCI-EORTC Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Puma Biotechnology grants inducement restricted stock unit award to new non-executive employee
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.22%
Tags
none
-
Rhea-AI Summary
Puma Biotechnology receives Orphan Drug Designation from FDA for alisertib in small cell lung cancer, indicating progress in development
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.34%
Tags
Rhea-AI Summary
Puma Biotechnology to present at H.C. Wainwright Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.93%
Tags
conferences
Puma Biotechnology, Inc.

Nasdaq:PBYI

PBYI Rankings

PBYI Stock Data

185.72M
29.40M
15.12%
66.91%
6.83%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
LOS ANGELES

About PBYI

we focus on in-licensing innovative drug candidates that are undergoing or have already completed initial clinical testing for the treatment of various forms of cancer and then seek to further develop these drug candidates for commercial use.